top of page

References

  1. Pai, M. et al. Tuberculosis. Nat. Rev. Dis. Primers 2, 16076. https://doi.org/10.1038/nrdp.2016.76 (2016).
     

  2. Kendall, E. A., Fofana, M. O., Dowdy, D. W. Burden of transmitted multidrug resistance in epidemics of tuberculosis: A transmission modelling analysis. Lancet Respir. Med. 3, 963–972. https://doi.org/10.1016/S2213-2600(15)00458-0. (2015).
     

  3. Sommerland, N. et al. Evidence-based interventions to reduce tuberculosis stigma: A systematic review. Int J Tuberc Lung Dis. 21, S81-S86. https://doi.org/10.5588/ijtld.16.0788. (2027).
     

  4. Pai, M., Dewan, P. K., Swaminathan, S. Transforming tuberculosis diagnosis. Nat. Rev. Microbiol. 8, 756–759. https://doi.org/10.1038/s41564-023-01365-3 (2023).
     

  5. Yang, F. et al. Bacteriophage therapy for the treatment of Mycobacterium tuberculosis infections in humanized mice. Nat Commun. 7, 294. https://doi.org/10.1038/s42003-024-06006-x. (2024).
     

  6. Wotale, T. W. et al. Identifying risk factors for recurrent multidrug resistant tuberculosis based on patient’s record data from 2016 to 2021: retrospective study. Sci. Rep. 14, 23912. https://doi.org/10.1038/s41598-024-73209-x. (2024).
     

  7. Zimmer, A. J. et al. Making cough count in tuberculosis care. Nat Commun. 2, 83. https://doi.org/10.1038/s43856-022-00149-w. (2022).
     

  8. Gharlameki, O. G., Colijn, C., Sekirov, I., Johnston, J. C., Sobkowiak, B. Early prediction of Mycobacterium tuberculosis transmission clusters using supervised learning models. Sci. Rep. 14, 27652. https://doi.org/10.1038/s41598-024-78247-z. (2024).
     

  9. Chitwood, M. H. et al. The recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova. Nat Commun. 15, 2962. https://doi.org/10.1038/s41467-024-47282-9. (2024).
     

  10. Turner, M. et al. Structural basis for allosteric modulation of M. tuberculosis proteasome core particle. Nat Commun. 16, 3138. https://doi.org/10.1038/s41467-025-58430-0. (2025).
     

  11. Arve-Aceves, M. F. et al. Fitness costs of Mycobacterium tuberculosis resistant to rifampicin is compensated by rapid Th2 polarization mediated by early and high IL-4 production during mice infection. Sci. Rep. 15, 2811 (2025). https://doi.org/10.1038/s41598-024-81446-3
     

  12. Dlangalala, T., Musekiwa, A., Mashamba-Thompson, T. Impact of COVID-19 on TB diagnostic services at primary healthcare clinics in eThekwini district, South Africa. Sci. Rep. 13, 16645. https://doi.org/10.1038/s41598-023-43589-7. (2023).
     

  13. Iglesias, M. J. et al. The value of the continuous genotyping of multi-drug resistant tuberculosis over 20 years in Spain. Sci. Rep. 10, 20433. https://doi.org/10.1038/s41598-020-77249-x. (2020).

     

  14. Codlin, A. J. et al. Independent evaluation of 12 artificial intelligence solutions for the detection of tuberculosis. Sci. Rep. 11, 23895. https://doi.org/10.1038/s41598-021-03265-0. (2021).
     

  15. Humphries, C. Latency: A sleeping giant. Nature 502, S14–S15. https://doi.org/10.1038/502S14a. (2013).
     

  16. The CRyPTIC Consortium. Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach. Nat. Commun. 15, 488. https://doi.org/10.1038/s41467-023-44325-5. (2024).
     

  17. Dai, R., Peng, S. The implication of the illness metaphors of In America: Mitigating negative effects of metaphors through illness narratives in the postpandemic era of COVID-19. Humanit. Soc. Sci. Commun. 11, 778. https://doi.org/10.1057/s41599-024-03308-7. (2025).
     

  18. Smith, J. P. et al. Characterizing tuberculosis transmission dynamics in high-burden urban and rural settings. Sci. Rep. 12, 6780. https://doi.org/10.1038/s41598-022-10488-2. (2022).
     

  19. Vikram, S. et al. Hydrogen sulfide stimulates Mycobacterium tuberculosis respiration, growth and pathogenesis. Nat. Commun. 11, 557. https://doi.org/10.1038/s41467-019-14132-y. (2020).
     

  20. Samuels, J. P., Sood, A., Campbell, J. R., Khan, F. A., Johnston, J. C. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Sci. Rep. 8, 4980. https://doi.org/10.1038/s41598-018-23344-z. (2018). 

  21. World Health Organization. Global Programme on Tuberculosis & Lung Health — The End TB Strategy. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/the-end-tb-strategy. (2015).

  22.  Results Canada. Investing in innovation and equitable access to end the tuberculosis epidemic. https://resultscanada.ca/wp-content/uploads/Results-TB-RD-Report-finalweb.pdf. (2024).

  23. Government of Canada. Tuberculosis in Indigenous communities. https://www.sac-isc.gc.ca/eng/1570132922208/1570132959826. (2025).

24. Government of British Columbia. First Nations Health Authority. https://www2.gov.bc.ca/gov/content/health/about-bc-s-health-          care-system/partners/health-authorities/first-nations-health-authority. (2017).

25. World Health Organization. Global Programme on Tuberculosis & Lung Health — The End TB Strategy.

      https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/the-end-tb-strategy. (2015).

26. World Health Organization. TB research and innovation. Global Tuberculosis Report 2023. https://www.who.int/teams/global-          programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2023/tb-research-and-innovation. (2023).

bottom of page